Markets.com Logo

TBIO

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    0.0217$
  • Previous Close
    0.0217$
  • 52 Week Change
    5.07$
  • Day Range
    0.00$
  • 52 Week High/Low
    0.012$ - 5.08$
  • Dividend Per Share
    --
  • Market cap
    39 068$
  • EPS
    -4.0938
  • Beta
    2.783
  • Volume
    --

About

TBIO.US represents the common stock of Translate Bio, Inc., a company formerly focused on developing messenger RNA (mRNA) therapeutics. Translate Bio was acquired by Sanofi in August 2021. Therefore, TBIO.US is no longer actively traded on the stock market, and its price history reflects its value prior to the acquisition. Prior to its acquisition, Translate Bio focused on developing mRNA therapeutics for various diseases, including cystic fibrosis and liver diseases.
Top 3 tech stocks to buy in 2026: Nebius (NBIS), MSTR stock, AAPL stock

Top 3 tech stocks to buy in 2026: Nebius (NBIS), MSTR stock, AAPL stock

Ghko B|--
BitGo crypto IPO: BitGo (BTGO) stock soars 20%, is BitGo a good buy?

BitGo crypto IPO: BitGo (BTGO) stock soars 20%, is BitGo a good buy?

Ghko B|--
S&P 500 forecast: Is the S&P 500 expected to go up in 2026?

S&P 500 forecast: Is the S&P 500 expected to go up in 2026?

Ghko B|--
Gold hits a new record above $4800: What is gold price prediction for 2026?

Gold hits a new record above $4800: What is gold price prediction for 2026?

Frances Wang|--
Trending tech stocks analysis: Intel stock jumps 12%, NVDA shares up 3%

Trending tech stocks analysis: Intel stock jumps 12%, NVDA shares up 3%

Frances Wang|--
Forex CFD trading platform reviews 2026: markets.com, IG, Avatrade

Forex CFD trading platform reviews 2026: markets.com, IG, Avatrade

Ghko B|--
ARK 21shares Bitcoin ETF (ARKB) analysis: Is ARKB a good investment?

ARK 21shares Bitcoin ETF (ARKB) analysis: Is ARKB a good investment?

Ghko B|--

Factors

Clinical Trial Results: Positive data boosts investor confidence, driving up demand and stock price. Negative results or trial failures often lead to significant price drops.

Regulatory Approvals: FDA approval of TBIO's drugs or therapies is a major catalyst, increasing revenue potential and stock valuation. Rejections or delays can negatively impact the stock.

Market Sentiment: General market trends, investor optimism or pessimism, and the overall health of the biotechnology sector influence TBIO's stock price.

Competition: The presence of competing products or companies in the same therapeutic area can affect TBIO's market share and stock performance.

Financial Performance: Revenue, earnings, and profitability reports impact investor perception of TBIO's value and future growth prospects.

Partnerships and Acquisitions: Collaborations with other companies or potential acquisition targets can lead to increased stock value.

People Also Watch

Latest news

ESMA Expansion Sparks Crypto, Fintech Slowdown Concerns in EU

ESMA Expansion Sparks Crypto, Fintech Slowdown Concerns in EU

Noah Lee|--
Bitcoin's 'Santa' Rally: Fed Rate Decision and 2026 Outlook

Bitcoin's 'Santa' Rally: Fed Rate Decision and 2026 Outlook

Noah Lee|--
Western Union Unveils Stable Card, Stablecoin Strategy to Combat Inflation

Western Union Unveils Stable Card, Stablecoin Strategy to Combat Inflation

Liam James|--

Latest Education Articles

S&P 500 trading for beginners: How to trade S&P 500 CFDs with markets.com?

S&P 500 trading for beginners: How to trade S&P 500 CFDs with markets.com?

Ghko B|--
Crypto day trading: How to day trade crypto CFDs with markets.com?

Crypto day trading: How to day trade crypto CFDs with markets.com?

Ghko B|--
Leverage trading: Difference between margin calls and forced liquidation

Leverage trading: Difference between margin calls and forced liquidation

Ghko B|--